Profile data is unavailable for this security.
About the company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
- Revenue in USD (TTM)925.00k
- Net income in USD-55.44m
- Incorporated2007
- Employees91.00
- LocationNeurogene Inc535 W 24Th Street, 5Th FloorNEW YORK 10011United StatesUSA
- Phone+1 (206) 732-2133
- Fax+1 (302) 655-5049
- Websitehttps://www.neurogene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compass Pathways PLC (ADR) | 0.00 | -139.21m | 506.07m | 186.00 | -- | 2.24 | -- | -- | -2.30 | -2.30 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -57.01 | -40.85 | -61.38 | -44.48 | -- | -- | -- | -- | -- | -52.52 | 0.1151 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -102.04m | 507.63m | 57.00 | -- | 2.25 | -- | -- | -2.26 | -2.26 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -49.75 | -- | -61.24 | -- | -- | -- | -- | -- | -- | -- | 0.1072 | -- | -- | -- | -68.55 | -- | -- | -- |
| Contineum Therapeutics Inc | -100.00bn | -100.00bn | 516.52m | 31.00 | -- | 2.37 | -- | -- | -- | -- | -- | 8.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -299.80m | 528.98m | 130.00 | -- | 0.9287 | -- | -- | -3.06 | -3.06 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -40.33 | -- | -43.71 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 35.19m | -86.45m | 535.03m | 116.00 | -- | -- | -- | 15.21 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 538.01m | 59.00 | -- | 3.53 | -- | 1,315.42 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Neurogene Inc | 925.00k | -55.44m | 540.01m | 91.00 | -- | 3.48 | -- | 583.80 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Eliem Therapeutics Inc | 0.00 | -64.20m | 555.26m | 9.00 | -- | 2.49 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Entrada Therapeutics Inc | 239.40m | 104.44m | 557.99m | 168.00 | 5.07 | 1.30 | 5.17 | 2.33 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 558.91m | 106.00 | -- | 1.90 | -- | 25.74 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Celcuity Inc | 0.00 | -82.59m | 562.49m | 55.00 | -- | 3.18 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 568.43m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 568.86m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 579.49m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Jun 2024 | 1.27m | 9.78% |
| RTW Investments LPas of 30 Jun 2024 | 1.07m | 8.24% |
| Redmile Group LLCas of 30 Jun 2024 | 1.01m | 7.80% |
| Great Point Partners LLCas of 30 Jun 2024 | 1.00m | 7.73% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 832.76k | 6.41% |
| BlackRock Advisors LLCas of 30 Jun 2024 | 742.93k | 5.72% |
| Avidity Partners Management LPas of 30 Jun 2024 | 727.54k | 5.60% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 619.90k | 4.77% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 549.41k | 4.23% |
| Casdin Capital LLCas of 30 Jun 2024 | 524.62k | 4.04% |
